Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.38 |
| ▸ | NCF1 | P14598 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725404 | 0.91 | SMN1; SMN2 (0.36) | L3MBTL1NCF1ALDH1A1LMNAMAPT | |
| SCHEMBL9668507 | 0.91 | SMN1; SMN2 (0.36) | L3MBTL1NCF1ALDH1A1LMNAMAPT | |
| SCHEMBL7281298 | 0.87 | L3MBTL1 (0.37) | L3MBTL1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL6238419 | 0.86 | JAK2 (0.33) | ALDH1A1LMNAMAPTTAAR1KDM4E | |
| SCHEMBL7157592 | 0.84 | RARB (0.40) | L3MBTL1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL7779040 | 0.84 | L3MBTL1 (0.37) | L3MBTL1ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL2499529 | 0.83 | LTA4H (0.34) | ALDH1A1 | |
| SCHEMBL126227 | 0.82 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL49802 | 0.82 | — | — | |
| SCHEMBL49991 | 0.81 | LTA4H (0.46) | L3MBTL1ALDH1A1MAPTKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | claimed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-11945152-B2 | Model material ink set, support material composition, ink set, three-dimensional shaped object, and method for manufacturing three-dimensional shaped object | MAXELL, LTD. (JP) | 2024-04-02 | — | — | US | disclosed |
| CN-116981658-A | Novel contrast agents for magnetic resonance imaging | 拜耳股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230174806-A1 | MODEL MATERIAL CLEAR COMPOSITION, MODEL MATERIAL COMPOSITION SET, AND COMPOSITION SET FOR OPTICAL SHAPING | MAXELL, LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-3578338-B1 | MODEL MATERIAL INK SET, SUPPORT MATERIAL COMPOSITION, INK SET, THREE-DIMENSIONAL SHAPED OBJECT, AND METHOD FOR MANUFACTURING THREE-DIMENSIONAL SHAPED OBJECT | MAXELL LTD (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20230100703-A1 | MODEL MATERIAL CLEAR COMPOSITION AND COMPOSITION SET FOR OPTICAL SHAPING | MAXELL, LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| CN-110105316-B | Resveratrol-phthalide hybrid compound and preparation method and application thereof | 合肥工业大学 | 2022-10-21 | — | — | CN | disclosed |
| US-6337304-B1 | HEAT EXCHANGING RECORDING IMAGE RECEIVERS AND DYES | KONICA CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
| US-5847218-A | Sulfonium salts and chemically amplified positive resist compositions | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| US-5804102-A | USE OF METAL COMPLEXES TO CUT OFF NEAR INFRARED RAYS; PREVENTION OF INTERFERENCE BETWEEN TELEVISION AND OTHER REMOTE CONTROLLED ELECTRONICS | MITSUI CHEMICALS, INC. (JP) | 1998-09-08 | — | — | US | disclosed |
| EP-0782164-A1 | Plasma display filter | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0190444-B1 | OPTICAL-RECORDING MEDIUM | BASF Aktiengesellschaft (DE) | 1988-09-21 | — | — | EP | disclosed |
| EP-0190444-A1 | Optical-recording medium | BASF Aktiengesellschaft (DE) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | L3MBTL1 1959/4885NCF1 3702/4885ALDH1A1 314/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | L3MBTL1 4582/4885NCF1 3079/4885ALDH1A1 260/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | L3MBTL1 4740/4885NCF1 2323/4885ALDH1A1 394/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | L3MBTL1 2007/4885NCF1 3776/4885ALDH1A1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.